Contact
searchSearch
HMP Global
Login

Videos

Alexandra Gomez-Arteaga, MD, and Elias Jabbour, MD
Videos
CAR T-Cell Therapy and Bispecific Antibodies Reshape Treatment Sequencing in Acute Lymphoblastic Leukemia
10/24/2026
Elias Jabbour, MD; Alexandra Gomez Arteaga, MD
Alexandra Gomez-Arteaga, MD, and Elias Jabbour, MD, discuss evolving treatment strategies for adult acute lymphoblastic leukemia, highlighting earlier CAR T-cell therapy, advances in bispecific antibodies, MRD-guided treatment selection, and...
Alexandra Gomez-Arteaga, MD, and Elias Jabbour, MD, discuss evolving treatment strategies for adult acute lymphoblastic leukemia, highlighting earlier CAR T-cell therapy, advances in bispecific antibodies, MRD-guided treatment selection, and...
Alexandra Gomez-Arteaga, MD, and...
10/24/2026
Oncology
Eunice Wang, MD, and Eytan Stein, MD
Videos
Menin Inhibitors Advance Targeted Treatment Strategies in NPM1-Mutated and KMT2A-Rearranged Acute Myeloid Leukemia
10/24/2026
Eytan Stein, MD
Eunice Wang, MD, and Eytan Stein, MD, discuss advances in menin inhibitor therapy for acute myeloid leukemia, highlighting the clinical activity of revumenib and ziftomenib, emerging combination strategies, mechanisms of acquired resistance,...
Eunice Wang, MD, and Eytan Stein, MD, discuss advances in menin inhibitor therapy for acute myeloid leukemia, highlighting the clinical activity of revumenib and ziftomenib, emerging combination strategies, mechanisms of acquired resistance,...
Eunice Wang, MD, and Eytan...
10/24/2026
Oncology
Paul Richardson, MD
Videos
Emerging Immunotherapies and Targeted Agents Advance Treatment of High-Risk Multiple Myeloma
10/24/2026
Paul Richardson, MD, discusses advances in high-risk multiple myeloma management, highlighting genomic and functional risk stratification, frontline quadruplet regimens, emerging immunotherapies, and novel CELMoDs such as iberdomide and...
Paul Richardson, MD, discusses advances in high-risk multiple myeloma management, highlighting genomic and functional risk stratification, frontline quadruplet regimens, emerging immunotherapies, and novel CELMoDs such as iberdomide and...
Paul Richardson, MD, discusses...
10/24/2026
Oncology
Pinkal Desai, MD
Videos
MRD-Guided Risk Stratification Refines Transplant Decisions in Patients With Acute Myeloid Leukemia
10/24/2026
Pinkal Desai, MD
Pinkal Desai, MD, discusses post-remission treatment strategies in acute myeloid leukemia, highlighting how molecular risk classification, measurable residual disease monitoring, and transplant-related risk guide allogenic stem cell...
Pinkal Desai, MD, discusses post-remission treatment strategies in acute myeloid leukemia, highlighting how molecular risk classification, measurable residual disease monitoring, and transplant-related risk guide allogenic stem cell...
Pinkal Desai, MD, discusses...
10/24/2026
Oncology
Joshua Richter, MD
Videos
MRD Assessment Advances Risk Stratification and Treatment Decision-Making in Multiple Myeloma
10/24/2026
Joshua Richter, MD
Joshua Richter, MD, discusses the evolving role of measurable residual disease assessment in multiple myeloma, highlighting its prognostic value, growing importance in clinical trials and regulatory decisions, and the need for prospective...
Joshua Richter, MD, discusses the evolving role of measurable residual disease assessment in multiple myeloma, highlighting its prognostic value, growing importance in clinical trials and regulatory decisions, and the need for prospective...
Joshua Richter, MD, discusses...
10/24/2026
Oncology
John Mascarenhas, MD
Videos
JAK Inhibitors and Emerging Combination Strategies Advance Personalized Treatment in Myelofibrosis
10/24/2026
John Mascarenhas, MD
John Mascarenhas, MD, discusses advances in myelofibrosis treatment, highlighting individualized JAK inhibitor selection, emerging CALR-targeted therapies, novel combination strategies involving pelabresib and selinexor, and ongoing efforts...
John Mascarenhas, MD, discusses advances in myelofibrosis treatment, highlighting individualized JAK inhibitor selection, emerging CALR-targeted therapies, novel combination strategies involving pelabresib and selinexor, and ongoing efforts...
John Mascarenhas, MD, discusses...
10/24/2026
Oncology
Videos
Individualizing First-Line Immunotherapy in Advanced cSCC: What Tolerability Trade-Offs Exist and How Do They Shape Real-World Use?
10/21/2026
Sunandana Chandra, MD; Solly Chedid, MD; Bahar Dasgeb, MD
10/21/2026
Oncology
Videos
Individualizing First-Line Immunotherapy in Advanced cSCC: How Should Pivotal Trial Data Guide First-Line Treatment Selection?
10/21/2026
Sunandana Chandra, MD; Solly Chedid, MD; Bahar Dasgeb, MD
In a fit, treatment-naive patient with good performance status, does the mature, multi-year efficacy and safety data behind anti-PD-1 agents outweigh the rationale for a newer, selective anti-PD-L1 option? Experts debate how follow-up...
In a fit, treatment-naive patient with good performance status, does the mature, multi-year efficacy and safety data behind anti-PD-1 agents outweigh the rationale for a newer, selective anti-PD-L1 option? Experts debate how follow-up...
In a fit, treatment-naive...
10/21/2026
Oncology
Videos
Immune Checkpoint Inhibition in Advanced cSCC: Perspectives From Clinical Practice
10/19/2026
David Portnoy, MD, FACP
10/19/2026
Oncology
Catherine Diefenbach, MD
Videos
Optimizing First-Line Treatment Selection Across in Early- and Advanced-Stage Hodgkin Lymphoma
10/15/2026
Catherine Diefenbach, MD
Catherine Diefenbach, MD, discusses evolving first-line treatment options for patients with classical Hodgkin lymphoma, highlighting findings from the S1826 and HD21 trials, the integration of nivolumab and AVD and brentuximab vedotin-based...
Catherine Diefenbach, MD, discusses evolving first-line treatment options for patients with classical Hodgkin lymphoma, highlighting findings from the S1826 and HD21 trials, the integration of nivolumab and AVD and brentuximab vedotin-based...
Catherine Diefenbach, MD,...
10/15/2026
Oncology

Recent News

News
Darolutamide Plus ADT and Radiotherapy Significantly Improves Metastasis-Free Survival in High-Risk Prostate Cancer
10/24/2026
Stephanie Holland
Results from the DASL-HiCaP trial demonstrated that adding darolutamide to androgen deprivation therapy and radiotherapy significantly improved metastasis-free survival in patients with very high-risk localized or biochemically...
Results from the DASL-HiCaP trial demonstrated that adding darolutamide to androgen deprivation therapy and radiotherapy significantly improved metastasis-free survival in patients with very high-risk localized or biochemically...
Results from the DASL-HiCaP...
10/24/2026
Oncology
News
Tarlatamab Plus Durvalumab Significantly Improves Overall Survival in Patients With Extensive-Stage Small Cell Lung Cancer
10/24/2026
Stephanie Holland
Results from the phase 3 DeLLphi-305 trial demonstrated that tarlatamab plus durvalumab significantly improved overall survival, progression-free survival, and objective response compared with durvalumab alone as first-line maintenance...
Results from the phase 3 DeLLphi-305 trial demonstrated that tarlatamab plus durvalumab significantly improved overall survival, progression-free survival, and objective response compared with durvalumab alone as first-line maintenance...
Results from the phase 3...
10/24/2026
Oncology
News
VOLGA Trial Demonstrates Significant Survival Benefit With Durvalumab Plus Enfortumab Vedotin in Muscle-Invasive Bladder Cancer
10/24/2026
Stephanie Holland
Results from the phase 3 VOLGA trial demonstrated that perioperative durvalumab plus neoadjuvant enfortumab vedotin significantly improved event-free and overall survival in cisplatin-ineligible or cisplatin-refusing patients with...
Results from the phase 3 VOLGA trial demonstrated that perioperative durvalumab plus neoadjuvant enfortumab vedotin significantly improved event-free and overall survival in cisplatin-ineligible or cisplatin-refusing patients with...
Results from the phase 3 VOLGA...
10/24/2026
Oncology
News
Intismeran Plus Pembrolizumab Significantly Improves Recurrence-Free Survival in Resected High-Risk Melanoma
10/24/2026
Stephanie Holland
Results from the phase 3 INTerpath-001 trial demonstrated that intismeran plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with resected high-risk...
Results from the phase 3 INTerpath-001 trial demonstrated that intismeran plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with resected high-risk...
Results from the phase 3...
10/24/2026
Oncology
FDA Approval
FDA Grants Full Approval to Pembrolizumab for Patients With Tumor Mutational Burden-High Solid Tumors
10/23/2026
Emily Estrada
Based on results from the KEYNOTE-158 trial, the FDA converted pembrolizumab’s accelerated approval to traditional approval for adult and pediatric patients with previously treated unresectable or metastatic tumor mutational burden-high...
Based on results from the KEYNOTE-158 trial, the FDA converted pembrolizumab’s accelerated approval to traditional approval for adult and pediatric patients with previously treated unresectable or metastatic tumor mutational burden-high...
Based on results from the...
10/23/2026
Oncology
FDA Approval
FDA Approves Dostarlimab for Patients With MSI-H/dMMR Locally Advanced Rectal Cancer
10/19/2026
Emily Estrada
The FDA granted accelerated approval to dostarlimab for patients with stage II/III MSI-H/dMMR locally advanced rectal cancer, establishing an immunotherapy-based treatment option supported by sustained clinical complete responses and the...
The FDA granted accelerated approval to dostarlimab for patients with stage II/III MSI-H/dMMR locally advanced rectal cancer, establishing an immunotherapy-based treatment option supported by sustained clinical complete responses and the...
The FDA granted accelerated...
10/19/2026
Oncology
FDA Approval
FDA Expands Nogapendekin Alfa Inbakicept Plus Bacillus Calmette-Guérin Approval to Include High-Grade Papillary-Only Bladder Cancer
10/14/2026
Emily Estrada
The FDA expanded the indication for nogapendekin alfa inbakicept plus Bacillus Calmette-Guérin (BCG) to include patients with high-grade papillary-only, BCG-unresponsive non-muscle-invasive bladder cancer, extending treatment eligibility...
The FDA expanded the indication for nogapendekin alfa inbakicept plus Bacillus Calmette-Guérin (BCG) to include patients with high-grade papillary-only, BCG-unresponsive non-muscle-invasive bladder cancer, extending treatment eligibility...
The FDA expanded the indication...
10/14/2026
Oncology
News
Pegylated Liposomal Doxorubicin Improves Progression-Free Survival in Patients With Advanced Desmoid Tumors
10/09/2026
Emily Estrada
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged progression-free survival and objective response compared with placebo in patients with advanced or refractory desmoid tumors, supporting...
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged progression-free survival and objective response compared with placebo in patients with advanced or refractory desmoid tumors, supporting...
Results from a phase 3 trial...
10/09/2026
Oncology
News
Iberdomide Plus Daratumumab and Dexamethasone Significantly Improves PFS in Relapsed or Refractory Multiple Myeloma
10/08/2026
Stephanie Holland
Topline results from the phase 3 EXCALIBER-RRMM trial demonstrated significantly prolonged progression-free survival with iberdomide plus daratumumab and dexamethasone compared with daratumumab, bortezomib, and dexamethasone in...
Topline results from the phase 3 EXCALIBER-RRMM trial demonstrated significantly prolonged progression-free survival with iberdomide plus daratumumab and dexamethasone compared with daratumumab, bortezomib, and dexamethasone in...
Topline results from the phase 3...
10/08/2026
Oncology
News
Cytarabine Induction Followed by Azacitidine and Lenalidomide Shows Activity in Very-High-Risk Myelodysplastic Syndromes
10/08/2026
Emily Estrada
Results from a small study evaluating a resource-adapted treatment strategy for very-high-risk myelodysplastic syndromes demonstrated responses with cytarabine induction followed by azacitidine and lenalidomide, supporting further...
Results from a small study evaluating a resource-adapted treatment strategy for very-high-risk myelodysplastic syndromes demonstrated responses with cytarabine induction followed by azacitidine and lenalidomide, supporting further...
Results from a small study...
10/08/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use